GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
789
c/t2dglp1·posted 3 days ago by u/britt_abubakar

[Results] A1c 9.1 → 5.4, full table, 14 months

Results Receipts ×4

A1c 9.1 → 5.4, full table, 14 months. Posting the boring middle of the process, because the internet is full of the start and the end and nothing else.

Figures up front so nobody has to dig: 14 months.

On hypoglycaemia, because the risk gets attributed to the wrong thing constantly.

Incretin-based agents stimulate insulin secretion in a glucose-dependent way: the effect scales with glycaemia rather than acting unconditionally. That is why monotherapy risk is low. Where risk rises substantially is in combination with agents that lower glucose independently of the current level.

Which means the question "does this cause hypos" is not answerable without knowing the rest of the regimen — and that the person who can answer it is the one who wrote the regimen. Nothing on this board is a substitute for that conversation, and the good threads here end by saying so.

The order things move in, since nobody explains it and it worries people.

Postprandial excursions generally respond earliest. Variability tends to narrow before the average does, which is visible on a sensor and invisible on a lab result. Fasting glucose is often the laggard, and A1c — being a three-month average — is the last thing to reflect anything.

So a month in which the sensor looks better and the fasting number has not moved is the ordinary sequence, not a contradiction. Knowing that in advance would have saved me a quarter of unnecessary worry, which is why it is worth writing down.

Ask me anything specific. Anything general I will probably get wrong.

1,203 up / 414 down74% upvoted44 commentsid 1sgmgz27 Jul 2026

44 comments

16 in this archive, depth 5

best — the order this archive was captured in

u/nadia_norgaard98 points·2 days ago

Certain conditions affect A1c independently of glycaemia. If a result looks inconsistent with the sensor data, that is a question for whoever manages your care rather than for this board.

replysharereportpermalink
[deleted]39 points·2 days ago

[deleted]

replysharereportpermalink
u/nhs_waitlist_nUK27 points·2 days ago

Postprandial excursions flattened out first and the fasting number took months to follow. Nobody had told me to expect that order.

replysharereportpermalink
u/laila_wikstrom141 points·2 days ago

The diabetes and obesity programmes are separate, with different populations and different primary endpoints. Reading a result across from one to the other is not a comparison.

replysharereportpermalink
u/sock_puppet_spotter96 points·2 days ago

The diabetes and obesity programmes are separate, with different populations and different primary endpoints.

laila_wikstrom is right that the fasting number moves last. Knowing that in advance saves months of worry.

replysharereportpermalink
load more comments (3) →
u/baseline_drifteranalytical88 points·1 days ago

Brought the whole CGM export to my appointment rather than one number. Entirely different conversation.

replysharereportpermalink
u/teodor_duarte70 points·1 days ago

Variability dropped before the average did, which was visible on the sensor and invisible on the lab result.

replysharereportpermalink
u/a1c_arcMOD25 points·22 hr ago

Retitled — the original quoted an obesity endpoint as a glycaemic one.

replysharereportpermalink
u/enzo_danquah39 points·2 days ago

Time in range told me far more than the average did. Two quarters with the same A1c looked completely different on the sensor.

replysharereportpermalink
u/throwaway_918214 points·2 days ago

Agreed on variability. Two people with the same average can have completely different days.

replysharereportpermalink
u/nadia_norgaard4 points·2 days ago

sensor accuracy varies and the first day of a sensor is the worst

replysharereportpermalink
u/laila_wikstrom1 point·2 days ago

CGM shows you the shape, A1c shows you the area

replysharereportpermalink
u/rafael_krastev1 point·1 days ago

Correction: that trial is the diabetes programme and the figure you quoted is its glycaemic endpoint, not a weight result.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/t2dglp1

Type 2 diabetes as the original indication: A1c trajectories, CGM traces, hypoglycaemia risk when stacked with sulfonylureas or insulin, metformin combinations, and why the weight-loss conversation sometimes drowns out the glycaemic one.

36kmembers
62submissions
Jun 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/t2dglp1 rules
  1. Insulin and sulfonylurea interactions are a real hypo risk. Do not hand-wave them.
  2. Post A1c with units and the assay date.
  3. No medication-stopping advice. Ever.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.